Want to see UNCY full AI Analyst Report?
UNCY Stock Chart & Stats
$7.02
-$0.03(-4.01%)
At close: 4:00 PM EST
$7.02
-$0.03(-4.01%)
Day’s Range― - ―
52-Week Range$3.71 - $8.74
Previous CloseN/A
Volume1.16M
Average Volume (3M)2.31M
Market Cap
$145.52M
Enterprise Value$103.67
Total Cash (Recent Filing)$54.59M
Total Debt (Recent Filing)$941.00K
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 17, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.05
Shares Outstanding26,700,027
10 Day Avg. Volume1,294,628
30 Day Avg. Volume2,313,189
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)30.36
Price to Sales (P/S)0.00
P/FCF Ratio-29.25
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$36.71Price Target Upside423.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.82
Revenue Forecast (FY)$4.23M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a materially improved equity base provide a durable financial cushion against operating losses. This reduces insolvency risk, preserves strategic optionality, and gives management time to advance clinical programs without immediate pressure to monetize assets or accept distressed financing.
Structural Financing FlexibilityAn enlarged at-the-market facility and a new shelf registration create ongoing, programmatic access to public capital. This structural funding option allows gradual, opportunistic raises to extend runway and consistently fund clinical development without relying on single large financings.
Focused Clinical Asset In Chronic IndicationOLC targets hyperphosphatemia in dialysis patients — a persistent, high-need condition with recurring treatment demand. If clinically successful, the drug could access a stable, durable market where repeat prescriptions and long-term adoption underpin sustainable revenue potential beyond initial approval.
Bears Say
No Revenue & Widening LossesSustained lack of product revenue and widening net losses indicate the company remains pre-revenue and dependent on development milestones. Continued operating losses erode equity, increase funding dependency, and concentrate investment risk on clinical outcomes rather than on diversified cash-generating operations.
Negative Free Cash FlowDeeply negative operating and free cash flow shows the business consumes significant cash to advance programs. Even with modest improvement, persistent burn necessitates external financing, limiting strategic flexibility and raising the likelihood of delayed programs or reduced R&D scope if capital access tightens.
Reliance On Equity Financing / Dilution RiskHeavy reliance on ATM facilities and shelf registrations signals dependence on equity markets to fund operations. Repeated issuances can materially dilute existing holders and depress per-share economics, creating a structural headwind to shareholder value absent eventual commercial revenues.
Unicycive Therapeutics News
UNCY FAQ
What was Unicycive Therapeutics, Inc.’s price range in the past 12 months?
Unicycive Therapeutics, Inc. lowest stock price was $3.71 and its highest was $8.74 in the past 12 months.
What is Unicycive Therapeutics, Inc.’s market cap?
Unicycive Therapeutics, Inc.’s market cap is $145.52M.
When is Unicycive Therapeutics, Inc.’s upcoming earnings report date?
Unicycive Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 26 days.
How were Unicycive Therapeutics, Inc.’s earnings last quarter?
Unicycive Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.459 by -$0.081.
Is Unicycive Therapeutics, Inc. overvalued?
According to Wall Street analysts Unicycive Therapeutics, Inc.’s price is currently Undervalued.
Does Unicycive Therapeutics, Inc. pay dividends?
Unicycive Therapeutics, Inc. does not currently pay dividends.
What is Unicycive Therapeutics, Inc.’s EPS estimate?
Unicycive Therapeutics, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Unicycive Therapeutics, Inc. have?
Unicycive Therapeutics, Inc. has 26,700,027 shares outstanding.
What happened to Unicycive Therapeutics, Inc.’s price movement after its last earnings report?
Unicycive Therapeutics, Inc. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.459. Following the earnings report the stock price went up 2.767%.
Which hedge fund is a major shareholder of Unicycive Therapeutics, Inc.?
Currently, no hedge funds are holding shares in UNCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Unicycive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.71 (423.00% Upside)
$36.71 (423.00% Upside)
Blogger Sentiment
Bullish
UNCY Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 263.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 18.3%
Last 30 Days ▲ 18.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
130.46%
Trailing 12-Months
Company Description
Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
UNCY Stock 12 Month Forecast
Average Price Target
$36.71
▲(423.00% Upside)
Technical Analysis
Ownership Overview
16.98%
Insiders
3.71% Mutual Funds
21.89% Other Institutional Investors
48.38% Public Companies and Individual Investors